BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23700879)

  • 1. Evaluation of tumor response to systemic therapy in hepatocellular carcinoma.
    Gafton B; Pârciu S; Murguleţ E; Bălan G
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1005-10. PubMed ID: 23700879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
    Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma.
    Kambadakone A; Baliyan V; Zhu AX
    Semin Liver Dis; 2017 Aug; 37(3):259-274. PubMed ID: 28847036
    [No Abstract]   [Full Text] [Related]  

  • 4. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads.
    Yeo DM; Choi JI; Lee YJ; Park MY; Chun HJ; Lee HG
    J Comput Assist Tomogr; 2014; 38(3):391-7. PubMed ID: 24681857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
    BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
    Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A; Miller FH; Kulik LM; Nikolaidis P; Yaghmai V; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Gupta R; Wang E; Baker T; Abecassis M; Benson AB; Nemcek AA; Omary R; Salem R
    JAMA; 2010 Mar; 303(11):1062-9. PubMed ID: 20233824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.
    Bargellini I; Vignali C; Cioni R; Petruzzi P; Cicorelli A; Campani D; De Simone P; Filipponi F; Bartolozzi C
    Radiology; 2010 Apr; 255(1):289-300. PubMed ID: 20308465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
    Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma.
    Koda M; Murawaki Y; Mitsuda A; Ohyama K; Horie Y; Suou T; Kawasaki H; Ikawa S
    Cancer; 2000 Feb; 88(3):529-37. PubMed ID: 10649243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I; Scionti A; Mismas V; Masi G; Vivaldi C; Bartolozzi C; Sacco R
    Oncology; 2014; 86(4):191-8. PubMed ID: 24800837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
    Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M
    Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
    Yaghmai V; Besa C; Kim E; Gatlin JL; Siddiqui NA; Taouli B
    AJR Am J Roentgenol; 2013 Jul; 201(1):80-96. PubMed ID: 23789661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy.
    Demeria D; Birchall I; Bain VG
    Can J Gastroenterol; 2007 Aug; 21(8):517-8. PubMed ID: 17703252
    [No Abstract]   [Full Text] [Related]  

  • 20. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Kim MJ; Choi JI; Lee JS; Park JW
    J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.